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INTRODUCTION
Hemangioblastoma (HB) of the central nervous system is
a benign neoplasm of the central nervous system that usual-
ly involves the brain and spinal cord. It may occur sporadi-
cally or in association with von Hippel-Lindau (VHL) disease
(1-5). In sporadic, non-VHL cases, the tumors are usually
solitary, and local recurrences are seen occasionally after surgery
(1, 2, 5). In contrast, HBs associated with VHL disease are
usually multiple and continue to arise over the course of a
patient’s life, which necessitates lifelong surveillance (2-5, 7).
Disseminated HB is an extremely unusual type of recurrence,
and it has recently been called hemangioblastomatosis (10-
16). Hemangioblastomatosis is very rare and has been report-
ed in patients with or without VHL. We report a case of
hemangioblastomatosis in a patient without VHL and dis-
cuss the biological and clinical features associated with this
disease.
CASE REPORT
In 1996, a 41-yr-old man underwent surgical excision of
a solitary cerebellar mass with the pathological diagnosis of
HB (Fig. 1A-C). He had no family history or clinical stigma-
ta to suggest the presence of VHL disease. Gross total removal
of the tumor was possible, and no evidence of residual or recur-
rent disease was observed on magnetic resonance imaging
(MRI) performed 1 yr after the surgery (Fig. 1D). Ten years
after the surgery, he returned to the hospital complaining of
low back pain and hypesthesia in his right posterior thigh.
MRI of the brain showed multiple mass lesions in the suprasel-
lar area and in the anterior aspect of the upper spinal cord
accompanied by diffuse leptomeningeal enhancement (Fig.
2A). Whole-spine MRI revealed numerous tiny enhancing
nodules suggestive of leptomeningeal metastasis along the
spinal cord and cauda equina (Fig. 2B). No retinal lesion was
found on examination of the fundus. Computed tomography
(CT) of the abdomen showed no abnormal findings. A blood
sample was collected from the patient after informed consent
was obtained. Genomic DNA was isolated from peripheral
blood leukocytes using a Wizard genomic DNA purification
kit according to the manufacturer’s instructions (Promega,
Madison, WI, U.S.A.). The three exons of the VHL gene as
well as their flanking introns were amplified and sequenced
by an ABI 3730 sequencer (AME Bioscience, Toroed, Nor-
way). Mutation was not found. The patient underwent sur-
gical resection of the cauda equina lesion and subtotal removal
of the tumor. Histopathological examination confirmed the
diagnosis of HB, and the microscopic findings were identical
to those of the cerebellar HB operated on 10 yr earlier (Fig.
2C). He subsequently received fractionated radiotherapy (a
total dose of 3,600 cGy) for a residual lesion in the cauda eq-
uina. Brain MRI scans obtained 6 months after the diagno-
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Disseminated Hemangioblastomatosis of the Central Nervous System
without von Hippel-Lindau Disease: A Case Report
We report a very rare case of hemangioblastomatosis that developed after surgical
removal of a solitary cerebellar hemangioblastoma (HB). A 51-yr-old man presented
with back pain 10 yr after undergoing surgery for cerebellar HB. Magnetic resonance
imaging showed numerous mass lesions along the entire neuraxis accompanied
by prominent leptomeningeal enhancement. Genomic DNA analysis showed no
mutation in the von Hippel-Lindau (VHL) genes. A surgical specimen obtained from
a lesion in the cauda equina showed pathological findings identical to those of the
cerebellar HB that had been resected 10 yr earlier. External beam radiation thera-
py and radiosurgery were subsequently performed; however, the patient succumbed
one year after receiving the diagnosis of hemangioblastomatosis. The reduction of
tumor cell spillage during surgery and regular long-term follow-up are recommend-
ed for patients with HBs. 
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Accepted : 3 March 2008sis of recurrence revealed interval growth of the suprasellar
lesion, and gamma knife radiosurgery was performed. He
also underwent ventriculoperitoneal shunt due to progressive
hydrocephalus. Although the treated lesions showed no fur-
ther growth, his condition gradually deteriorated with gen-
eral weakness, anorexia, and frequent vomiting. The patient
died of septic shock and respiratory failure at 1 yr after the
diagnosis of disseminated recurrence.
DISCUSSION
HBs account for 1 to 2% of primary intracranial tumors
and 5 to 15% of posterior fossa tumors in adults (2-5, 7, 8).
Approximately 62% of HBs arise sporadically, and 38% occur
in association with VHL disease (6). The average age at pre-
sentation of sporadic cerebellar HBs is approximately 35 yr,
and these tumors are more common in men. HB is thought
to be a benign tumor curable by microsurgery; however, sev-
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Fig. 1. Initial magnetic resonance images, pathology finding and postoperative MR images in first diagnosis. (A, B) Initial T1-weighted
magnetic resonance images obtained after gadolinium infusion. Sagittal and axial images of the brain showing a well-enhanced cerebel-
lar mass but no mass in the suprasellar or cervicovertebral junction. (C) Pathology microphotograph stained with hematoxylin and eosin
(×400) showing large vacuolated stromal cells that have larger, hyperchromatic nuclei and an eosinophilic foamy cytoplasm. It is char-
acterized by the accumulation of lipid droplets within stromal cells and a rich capillary network. (D) T1-weighted magnetic resonance images
taken 1 yr after surgery. There was no evidence of residual or recurrent disease on MR images.
C
B A
Deral previous studies have reported that the recurrence rate
after surgical excision is 15-27% (9).
VHL disease is an autosomal-dominant neoplasia syndrome
caused by a germline mutation or deletion on the short arm
of chromosome 3. Patients with VHL tend to present with
neurological symptoms and signs at a younger age than those
with sporadic disease. The syndrome is characterized by the
development of multiple visceral and central nervous system
(CNS) lesions. Tumors of the CNS include HBs, which affect
48-80% of patients with predisposing sites in the cerebellum
(44-73%), brainstem (10-25%), spinal cord (13-50%), and
retina (25-60%), as well as endolymphatic sac tumors, which
affect 10-15% of patients (17-19). The visceral lesions include
renal cell carcinoma, renal cyst, pheochromocytoma, pancre-
atic cyst, and pancreatic neuroendocrine tumor. Cystadenomas
of the epididymis and broad ligament may also be present. 
Disseminated HB is a distinct but very rare type of HB
recurrence. Only 12 cases of disseminated HB have been
reported previously (10-16). Mohan et al. (11) first reported
two cases of disseminated HB that developed several years
after complete excision. Bakshi et al. (10) reported a case of
diffuse spinal leptomeningeal enhancement on MRI associ-
ated with multiple HBs and termed this condition heman-
gioblastomatosis. All 12 previously reported cases of dissem-
inated HB arose in patients who had solid cerebellar HB as
a primary lesion, and 9 of the patients had no association with
VHL disease (10-16). All of the patients underwent surgical
treatment of the primary lesion, and hemangiomatosis devel-
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Fig. 2. Brain and lumbar magnetic resonance images and the
pathology finding in disseminated recurrence. (A) T1-weighted
magnetic resonance images obtained after gadolinium infusion.
Sagittal view of the brain showing an enhancing mass in the
suprasellar area with prominent leptomeningeal enhancement
and another enhancing mass ventral to the upper spinal cord.
(B) Sagittal view of the lumbar spine showing multiple enhanc-
ing nodules within the thoracolumbar spinal canal. (C) Histo-
pathological photograph obtained from the mass in the cauda
equina, which was stained with hematoxylin and eosin (×200).
The architecture of tissue cells and morphology of the cells are
identical with that of the cerebellar tumor shown in Fig. 1A.
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+ 14.28 mmoped after variable intervals ranging from 6 months to 22 yr.
In reported cases, biopsy specimens from the primary and
secondary lesions were similar in histopathology to that in
our case. No mitoses or signs of cellular anaplasia were seen.
Tumor infiltration to leptomeninges was identified in five cases
by MRI demonstrating diffuse leptomeningeal enhancement
on the surface of the brainstem and spinal cord (10, 12, 14-
16). The outcomes after recurrence were very poor, and most
patients died within 3 yr. The most common cause of death
was respiratory failure due to pontomedullary or cervical cord
compression. The currently available treatment did not have
a significant effect on the progression of the disease. Eight
patients with disseminated HB received from 13 to 56 Gy
of irradiation to the posterior fossa or spinal cord; however,
long-term tumor control was not achieved (11-16). Advanced
radiation techniques, such as radiosurgery, may be more effec-
tive than conventional fractionated radiotherapy, but it is dif-
ficult to perform high-dose radiation therapy or radiosurgery
for numerous lesions scattered throughout the entire neuraxis.
The use of interferon-α , thalidomide or a vascular endothe-
lial growth factor receptor antagonist to inhibit angiogene-
sis (20, 21) did not result in remarkable tumor response. 
Though VHL gene mutation was not detected in our case,
the VHL gene may be mutated in sporadic cases of HB of
the CNS (7). In a molecular genetic analysis of four cases of
hemangioblastomatosis without VHL, Weil et al. (14) found
no evidence of germline alterations in the VHL gene, but the
somatic deletion of one copy of the VHL gene. These findings
implicate a monoclonal origin of multiple, separate deposits
of tumors in patients with sporadic HB. The results of com-
parative genomic hybridization studies suggest that other
genes, in addition to the VHL gene, may be involved in the
dissemination of HBs (15).
Because no case of de novo development of disseminated
HB without previous surgery has been reported, it is strongly
suggested that the spillage and spread of tumor cells through
the CSF space may be an origin of hemangioblastomatosis in
patients with a genetic predisposition to the condition. All
previously reported cases showed multiple mass lesions exclu-
sively in the infratentorial area and spinal cord except only
one case (13). Our case is the second case uniquely present-
ing with additional lesions in supratentorial space. Paucity
of supratentorial lesions may reflect CSF flow and effect of
gravity supporting the hypothesis of tumor spread through
CSF pathway. Preventive measures to reduce tumor cell spi-
llage should be considered during operation, and further study
to determine the biological risk factors of disseminated recur-
rence is needed.
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